SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cambridge Antibody Technology Group PLC Licenses Monoclonal Antibody (CAT-213) For Treatment Of Allergy Disorders To iCo Therapeutics Inc.